Home > Services > New Indications and Reprofiling

Drug Reprofiling

Biopharma companies need today to maximize the value of their pipeline, and one of the strategies is to identify new indications for drugs already in the clinical stages of clinical development, where the compounds have proven to be safe, but not yet effective enough for the intended initial indication. Drug reprofiling has to be a directed, rational and optimized process, where new indications can be predicted and identified in weeks, not in months. For doing so, Anaxomics' Systems Biology approaches explores the full potential of the analysis of the biochemical networks in order to identify the new indications for your drugs. In our Global Collaborative Initiative, we offer biopharma companies all over the world a quick and systematyic analysis of their pipeline, in a flexible model that may consist on a fee-for-service approach, or a shared-risk approach, depending on the clients' wish.

Anaxomics has already identified a number of compounds and combinations active in Alzheimer Disease by using our drug-reprofiling systems.

We apply the following processes to maximize the chances of success of any Drug Reprofiling project:

• Copyright (c) Anaxomics 2010
• Privacy policy
• Legal disclaimer